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Abstract
Roach, Robert C., Peter H. Hackett, Oswald Oelz, Peter Ba¨rtsch, Andrew M. Luks, Martin J. MacInnis,
J. Kenneth Baillie, and The Lake Louise AMS Score Consensus Committee. The 2018 Lake Louise Acute
Mountain Sickness Score. High Alt Med Biol. 19:4–6, 2018.— The Lake Louise Acute Mountain Sickness (AMS)
scoring system has been a useful research tool since first published in 1991. Recent studies have shown that disturbed
sleep at altitude, one of the five symptoms scored for AMS, is more likely due to altitude hypoxia per se, and is not
closely related to AMS. To address this issue, and also to evaluate the Lake Louise AMS score in light of decades of
experience, experts in high altitude research undertook to revise the score. We here present an international consensus
statement resulting from online discussions and meetings at the International Society of Mountain Medicine World
Congress in Bolzano, Italy, in May 2014 and at the International Hypoxia Symposium in Lake Louise, Canada, in
February 2015. The consensus group has revised the score to eliminate disturbed sleep as a questionnaire item, and has
updated instructions for use of the score.
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Introduction
Acute mountain sickness (AMS) is the most commonform of acute altitude illness and typically occurs in
unacclimatized persons ascending to altitudes >2500 m, al-
though it can develop at lower altitudes in highly susceptible
individuals. Established risk factors include rate of ascent,
altitude reached, and individual predisposition. With 25 years
of use in hundreds of publications, the Lake Louise AMS score
has provided a robust and practical tool for researchers to
diagnose and to score the severity of AMS. Recent opinion
(Milledge, 2014) and research (MacInnis et al., 2013; Hall
et al., 2014) have suggested that updating the Lake Louise
AMS score is in order. This article outlines the brief historical
background, reviews diagnostic criteria, describes modifica-
tions to the score, and offers suggested experimental proce-
dures that may improve the use of the score in future studies.
Background
At the 1991 International Hypoxia Symposium, the partici-
pants executed a consensus process chaired by Peter Hackett and
Oswald Oelz (Hackett et al., 1992; supplementary reprint of
original article is available online at www.liebertpub.com/ham)
to define and quantify the various altitude illnesses. Subsequently
at the 1993 conference, all delegates were given the opportunity
to have input into the preparation of the document. The score for
AMS consisted of the five symptoms (headache, gastrointestinal
upset, fatigue/weakness, dizziness/light-headedness, and sleep
disturbance), rated on a scale of severity from 0 to 3. The double-
worded terms were to facilitate understanding as well as trans-
lation into many languages (Roach et al., 1993; supplementary
reprint of original article is available online at www.liebertpub.
com/ham). A total score ‡3, in the presence of a headache, was
considered diagnostic for AMS.
Methods
This effort is the result of online discussions and meetings
at the International Society of Mountain Medicine World
Congress in Bolzano, Italy, in May 2014 and at the Interna-
tional Hypoxia Symposium in Lake Louise, Canada, in
February 2015. Members of the consensus committee are
those who have participated in the online or in-person dis-
cussions and are listed in alphabetical order in the box.
Rationale for Revising the Lake Louise AMS Score
Although use of the scoring system has helped standardize
the diagnosis and severity of AMS across research studies,
debate has persisted since its inception regarding whether sleep
should be included in the diagnostic criteria. Recently this
discussion has intensified. Two independent reports in 2013
provided empirical evidence that sleep disturbance is discordant
from other symptoms of AMS (MacInnis et al., 2013; Hall
et al., 2014). Hall et al. (2014) used network analysis of data
from 292 research volunteers exposed to altitudes from 3650 to
5200 m to demonstrate that sleep disturbance correlated poorly
with other symptoms of AMS. Importantly, sleep disturbance
was absent in 40% of cases with severe headache, long con-
sidered a hallmark of AMS. MacInnis et al. (2013) applied
factor analysis to Lake Louise AMS scores of 491 Nepalese
pilgrims at 4390 m and revealed that sleep had only a weak
relationship with the other four symptoms in the score. Milledge
also expressed doubt as to whether sleep disturbance was a
symptom of AMS, or rather an effect of hypoxia per se, based
on his own experience with AMS studies (Milledge, 2014).
Another problem recognized over time is that many studies of
AMS have used only daytime exposures, making the sleep
component irrelevant. Without a score for sleep in these studies,
comparison with overnight studies is difficult. Based on these
concerns, the consensus committee recommends that the sleep
component be removed from the Lake Louise AMS score.
Diagnostic Criteria and Assessment of AMS
AMS is defined as a Lake Louise AMS score total of three
or more points from the four rated symptoms, including at
least one point from headache in the setting of a recent ascent
or gain in altitude (Roach et al., 2011; West, 2011) (Table 1).
Some authors have suggested a higher cutoff for diagnosing
AMS (Maggiorini et al., 1998; Ba¨rtsch et al., 2004), but the
consensus committee believes that by eliminating the sleep
question, more people with true AMS will be identified at the
threshold of three points, including headache. Sufficient re-
search is lacking to divide the score into severity rankings.
For those who wish to do so, we suggest mild AMS as 3–5
points, moderate AMS as 6–9 points, and severe AMS as 10–
12 points. Although symptoms can develop within 6 hours of
gain in altitude, we recommend assessing AMS score only
after 6 hours, to avoid confusing AMS with confounding
symptoms from travel or responses to acute hypoxia (e.g.,
vagal responses). If investigators wish to assess the impact of
AMS symptoms on overall function at high altitude, the
‘‘AMS Clinical Functional Score’’ is available (Table 1).
Table 1. 2018 Lake Louise Acute Mountain
Sickness Score
Headache
0—None at all
1—A mild headache
2—Moderate headache
3—Severe headache, incapacitating
Gastrointestinal symptoms
0—Good appetite
1—Poor appetite or nausea
2—Moderate nausea or vomiting
3—Severe nausea and vomiting, incapacitating
Fatigue and/or weakness
0—Not tired or weak
1—Mild fatigue/weakness
2—Moderate fatigue/weakness
3—Severe fatigue/weakness, incapacitating
Dizziness/light-headedness
0—No dizziness/light-headedness
1—Mild dizziness/light-headedness
2—Moderate dizziness/light-headedness
3—Severe dizziness/light-headedness, incapacitating
AMS Clinical Functional Score
Overall, if you had AMS symptoms, how did they affect
your activities?
0—Not at all
1—Symptoms present, but did not force any change in
activity or itinerary
2—My symptoms forced me to stop the ascent or to go
down on my own power
3—Had to be evacuated to a lower altitude
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AMS must not be confused with high-altitude cerebral edema
(HACE). AMS alone exhibits no neurological findings, and is
self-limited. In contrast, HACE, which usually comes on be-
tween 24 and 72 hours after a gain in altitude, is characterized by
change in mental status and/or ataxia, occurs usually in a person
with AMS or high-altitude pulmonary edema, and is a medical
emergency (Hackett and Roach, 2004; Willmann et al., 2014).
Directions for Using the Lake Louise AMS Score
This Lake Louise AMS score is for use by investigators
studying AMS. It is not intended for use by clinicians, pro-
fessional outdoor guides, and laypersons to diagnose or
manage AMS. After a recent gain in altitude or induction of
hypoxia, and an exposure of at least 6 hours duration, the
AMS score is used as follows:
1. The Lake Louise AMS score is designed as a self-
report questionnaire that research volunteers complete
on their own. However, some investigators prefer to
read the question to the volunteer and record the an-
swers, whereas others use a two-step method wherein
the volunteer first completes the score, then the in-
vestigator verbally verifies the answers. These options
are acceptable as long as a uniform approach is used
with all subjects in a study and the method of col-
lecting data is clearly described in subsequent reports.
2. The Lake Louise AMS score for an individual is the sum
of the score for the four symptoms (headache, nausea/
vomiting, fatigue, and dizziness/light-headedness). For a
positive AMS definition, it is mandatory to have a head-
ache score of at least one point, and a total score of at least
three points.
Example 1: A total score greater than two points but
with no headache is defined as NO AMS for research
purposes, although absence of a headache does not
exclude a diagnosis for clinical purposes.
Example 2: A score of three points for a severe head-
ache, with no other AMS symptoms, is defined as AMS.
3. We suggest using the AMS clinical functional score
and reporting it when suitable to the study design
(Roach et al., 1993; supplementary reprint of original
article is available online at www.liebertpub.com/ham;
Meier et al., 2017).
Avenues for Future Research
Further research should focus on the following areas: (1) best
methods for Lake Louise AMS score administration; that is,
is investigator-led scoring different/better than volunteer-
completed scores? (2) the impact of experimental design, the
testing environment, and expectations of research volunteers
(i.e., nocebo) (Benedetti et al., 2014) on reliability of Lake
Louise AMS score; (3) the clinical and functional impact(s) of
AMS score severity; (4) best practices for use of the Lake Louise
AMS score and clinical functional score by nonexpert clinicians,
mountain guides, and laypersons (Roach et al., 1993; supple-
mentary reprint of original article is available online at www
.liebertpub.com/ham; Meier et al., 2017); (5) the impact of dis-
turbed sleep on overall well-being at high altitude, independent
of AMS; and (6) the pathophysiology of typical AMS vs. pre-
sentation without headache (Roach et al., 2011; West, 2011). In
addition, we strongly encourage researchers to publish all in-
dividual scores for all volunteers and all symptoms. This will
allow other researchers to directly compare patterns of illness,
to compile meta-analyses, and to examine the raw data for ideas
and observations that will further refine the consensus defini-
tion and scoring of AMS.
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